Tournigand DREAM 2015.

Methods	Phase III RCT; n = 452
Participants	People with unresectable mCRC after initial bevacizumab‐including therapy (mFOLFOX7 with bevacizumab, CAPOX with bevacizumab, or FOLFIRI with bevacizumab)
Interventions	Arm A: maintenance combination of bevacizumab and erlotinib. Arm B: maintenance bevacizumab
Outcomes	Primary endpoint: maintenance PFS. Secondary endpoints: PFS from inclusion, OS, safety
Notes	Sponsored by GERCOR and F. Hoffmann‐La Roche. Tournigand: grants from Roche, Sanofi, Merck, Amgen, Bayer. de Gramont: personal fees for talks and participation in advisory boards from Roche and Sanofi‐Aventis Median follow‐up: 48 to 51 months
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The random allocation sequence was generated through a computer random number generator.
Allocation concealment (selection bias)	Unclear risk	An unblinded randomisation (1:1) was done with a minimisation technique.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	High risk	No statement of central or blinded review of imaging to determine PFS ‐ awaiting response from authors
Incomplete outcome data (attrition bias) All outcomes	Low risk	Not stated, but 6/228 participants in bevacizumab arm and 4/224 participants in bevacizumab + erlotinib arm discontinued treatment due to "patient choice". In addition, long median follow‐up and balance of participants characteristics make significant attrition bias unlikely.
Selective reporting (reporting bias)	Low risk	All outcomes reported.
Other bias	Low risk	No other potential biases detected.